ArticleLipids in health and disease2021
Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population.
Article in Lipids in health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Triglyceride glucose waist circumference and non alcoholic fatty liver disease: a systematic review and meta analysis.BMC gastroenterology · 2025Pooled it
- Pooled it
- Pooled it
- The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Triglyceride glucose-body mass index as a practical screening tool for metabolic dysfunction-associated steatotic liver disease in older adults: A community-based cohort study.Asia Pacific journal of clinical nutrition · 2026Article
- Reduced Cardiovascular Risk Indicated by Changes in Triglyceride-Glucose Index After Pancreas Transplantation.Annals of transplantation · 2026Article
- Article
- Triglyceride Glucose-Body Mass Index Is Related With Arterial Stiffness in Adults: A Cross-Sectional Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study.Scientific reports · 2026Article
- Diagnostic Performance of Six Insulin Resistance Indices for MAFLD Across BMI Categories in Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Article
- Optimal obesity and lipid-related predictors of diabetes mellitus in middle-aged and elderly patients with liver disease in China: a CHARLS cross-sectional study.Diabetology international · 2025Article
- The role of Triglyceride-Glucose index in predicting pre-DM risk among Chinese adults.Scientific reports · 2025Article
- The association of the metabolic score for insulin resistance and metabolic dysfunction-related steatosis liver disease: a population-based observational study.European journal of medical research · 2025Observational
- Multimodal machine learning-based marker enables the link between obesity-related indices and future stroke: a prospective cohort study.EClinicalMedicine · 2025Article
- Predictive value of triglyceride glucose index in non-obese non-alcoholic fatty liver disease.BMJ open · 2025Observational
- Association between TyG-BMI and early-onset hypertension: evidence from NHANES.Scientific reports · 2025Article
- Association between TyG-related parameters and NAFLD risk in Japanese non-obese population.Scientific reports · 2025Article
- Association between triglyceride glucose-body mass index and gestational diabetes mellitus: a prospective cohort study.BMC pregnancy and childbirth · 2025Article
- Association between TyG related parameters and metabolic dysfunction associated fatty liver disease among nondiabetic individuals.Scientific reports · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriglyceride glucose-body mass index (TyG-BMI) is a recently developed alternative indicator to identify insulin resistance. However, few studies have investigated the association between the TyG-BMI and nonalcoholic fatty liver disease (NAFLD). Therefore, this study aimed to study the relationship between NAFLD and the TyG-BMI in the general population and its predictive value.
methodsA cross-sectional study was conducted on 14,251 general subjects who took part in a comprehensive health examination. The anthropological characteristics and many risk factors for NAFLD were measured.
resultsAfter fully adjusting for confounding variables, a stable positive correlation was found between NAFLD and the TyG-BMI (OR: 3.90 per SD increase; 95% CI: 3.54 to 4.29; P-trend< 0.00001). This positive correlation was not simply linear but a stable non-linear correlation. Additionally, obvious threshold effects and saturation effects were found, in which a threshold effect occurred when the TyG-BMI was between 100 and 150; when the TyG-BMI was between 300 and 400, the corresponding NAFLD risk appeared saturated. Furthermore, receiver operating characteristic analysis showed that the TyG-BMI could better predict the risk of NAFLD than other traditional indicators [TyG-BMI (AUC): 0.886; 95% CI: 0.8797-0.8927; P < 0.0001], particularly among young and middle-aged and non-obese people.
conclusionsThis epidemiological study is the first on the association between the TyG-BMI and NAFLD risk in the general population. In this large data set from the general population, the TyG-BMI showed an independent positive correlation with NAFLD. The discovery of the threshold effect and saturation effect between them provides a new idea to prevent and treat NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.